Question-and-Answer Session
Operator
Your first question comes from the line of Lia Hartmann with CRT Capital, please proceed.
Lia Hartmann – CRT Capital
Good morning everyone.
Alan Kessman
Good morning Lia.
Lia Hartmann – CRT Capital
First of all congratulations on the good cost control and I believe you had guided us to $60 million at the end of 2007, it’s so nice to see a number beyond that. I was wondering for clarification on the Phase II trial that you expect to conclude the data gathering shortly so have all patients now come off drug, and you need to lock the database?
Ann Cahill
Hi Lia, this is Ann Cahill. Well, in this trial the treatment is given on day one as you remember so patients get treated on day one for induction of remission and then are followed. There are no patients on the initial part of this study who are continued to get treated. However, we have kept this study open in EKG sub-study to fulfill an ICH guideline on the effect of the drug on the heart. So the answer to your question is two part. Number one, the patients on the initial part of this study have been treated and we’re just continuing to gather their response and duration of response data as well as status. Patients on the EKG sub-study continue to be enrolled at a selected number of sites.
Lia Hartmann – CRT Capital
Okay. And yes, I wasn’t clear on asking my question because I knew about the EKG, a follow on the study so thank you for that, and then also for you Ann, is there update yet with respect to presentations, or abstracts, or papers that have been accepted or put to ASCO for presentation?
Ann Cahill
Yes. I’m pleased that our abstracts submission to ASCO has been accepted for the Phase II study, and will be part of a poster discussion at ASCO in this year.
Lia Hartmann – CRT Capital
That’s terrific news, thank you. And that’s most likely the next scientific conference at which we would see Vion’s pipeline having a presence?
Ann Cahill
Yes. We will be on this summer both at ASCO and at the large Hematology Conference in Europe, the European ash equivalent EHA which is in June, and we’ll have presentations of data at both those meetings.
Lia Hartmann – CRT Capital
Okay. Good luck to everyone at Vion.
- To read the full transcript on Seeking Alpha, click here »
